The inflammasome in leprosy skin lesions: an immunohistochemical evaluation

Imagem de Miniatura
Arquivos
art_SILVA_The_inflammasome_in_leprosy_skin_lesions_an_immunohistochemical_2018.PDF (4.95 MB)
Citações na Scopus
12
Tipo de produção
article
Data de publicação
2018
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
DOVE MEDICAL PRESS LTD
Autores
SILVA, Luciana Mota
SOUSA, Jorge Rodrigues de
HIRAI, Kelly Emi
DIAS JR., Leonidas Braga
FURLANETO, Ismari Perini
CARNEIRO, Francisca Regina Oliveira
AARAO, Tinara Leila de Souza
Citação
INFECTION AND DRUG RESISTANCE, v.11, p.2231-2240, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective: Leprosy is a chronic infectious disease presenting with a spectrum of clinical manifestations that correspond to the type of immune response that develops in the host. Factors that may be involved in this process include inflammasomes, cytosolic proteins responsible for the activation of caspase 1, IL-1 beta and IL-18 secretion, and induction of a type of death called pyroptosis. Patients and methods: We evaluated the expression of inflammasome markers (nucleotidebinding oligomerization domain-like receptor containing pyrin domain 1 [NLRP1], nucleotidebinding oligomerization domain-like receptor containing pyrin domain 3 [NLRP3], caspase 1, IL-1 beta, and IL-18) by immunohistochemistry in 43 samples of skin lesions of leprosy patients from the groups indeterminate (I) leprosy (13 patients), tuberculoid (TT) leprosy (15 patients), and lepromatous leprosy (LL; 15 patients). Results: The evaluated markers were most upregulated in LL lesions, followed by lesions of TT leprosy and I leprosy. Differences were statistically significant between the I leprosy and LL leprosy forms and between the I leprosy and TT leprosy forms. Positive and significant correlations were found between IL-18 and caspase 1 in LL (r=0.7516, P=0.0012) and TT leprosy (r=0.7366, P=0.0017). In I leprosy, correlations were detected between caspase 1 and IL-1 beta (r=0.6412, P=0.0182), NLRP1 and IL-18 (r=0.5585, P=0.473), NLRP3 and IL-18 (r=0.6873, P=0.0094), and NLRP1 and NLRP3 (r=0.8040, P=0.0009). Conclusion: The expression of inflammasome markers in LL lesions indicates the ineffectiveness of this protein complex in controlling the infection. Caspase 1 may be involved in the pyroptotic cell death in the lepromatous form of the disease. Inflammasomes may act together in the initial phase of I leprosy; this phenomenon may influence the clinical outcome of the disease.
Palavras-chave
IL-1 beta, NLRP, Mycobacterium leprae, immune response, pyroptosis
URI
https://observatorio.fm.usp.br/handle/OPI/30061
Referências
  1. Amin J, 2017, BRAIN PATHOL, V27, P192, DOI 10.1111/bpa.12479
  2. Awad F, 2018, PHARMACOL THERAPEUT, V187, P133, DOI 10.1016/j.pharmthera.2018.02.011
  3. Briken V, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00062
  4. Broz P, 2016, NAT REV IMMUNOL, V16, P407, DOI 10.1038/nri.2016.58
  5. Cardoso CC, 2011, FUTURE MICROBIOL, V6, P533, DOI [10.2217/FMB.11.39, 10.2217/fmb.11.39]
  6. Chavarria-Smith J, 2015, IMMUNOL REV, V265, P22, DOI 10.1111/imr.12283
  7. Costa RD, 2008, REV SOC BRAS MED TRO, V41, P99, DOI 10.1590/S0037-86822008000700020
  8. Lira MLD, 2015, AM J DERMATOPATH, V37, P269
  9. de Sousa JR, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01635
  10. Duluc D, 2014, J IMMUNOL, V192, P5776, DOI 10.4049/jimmunol.1301661
  11. Eichelmann K, 2013, ACTAS DERMO-SIFILOGR, V104, P554, DOI [10.1016/j.ad.2012.03.003, 10.1016/j.adengl.2012.03.028]
  12. Elamin AA, 2012, J PATHOG, DOI 10.1155/2012/361374
  13. Engwerda CR, 2000, IMMUNOL TODAY, V21, P73, DOI 10.1016/S0167-5699(99)01549-2
  14. Evavold CL, 2018, J MOL BIOL, V430, P217, DOI 10.1016/j.jmb.2017.09.019
  15. Fernandez DJ, 2015, BIOL CHEM, V396, P193, DOI 10.1515/hsz-2014-0253
  16. Garcia VE, 1999, J IMMUNOL, V162, P6114
  17. Garib FY, 2016, BIOCHEMISTRY-MOSCOW+, V81, P1326, DOI 10.1134/S0006297916110109
  18. Gringhuis SI, 2012, NAT IMMUNOL, V13, P246, DOI 10.1038/ni.2222
  19. Kang TJ, 2010, MEDIAT INFLAMM, DOI 10.1155/2010/708713
  20. Kesavardhana S, 2017, INT IMMUNOL, V29, P201, DOI 10.1093/intimm/dxx018
  21. Lamkanfi M, 2017, J EXP MED, V214, P3147, DOI 10.1084/jem.20171848
  22. Lechtenberg BC, 2014, CURR OPIN STRUC BIOL, V29, P17, DOI 10.1016/j.sbi.2014.08.011
  23. Lee HM, 2012, IMMUNOL CELL BIOL, V90, P601, DOI 10.1038/icb.2011.72
  24. Lima DS, 2013, NAT MED, V19, P909, DOI 10.1038/nm.3221
  25. Lu A, 2015, FEBS J, V282, P435, DOI 10.1111/febs.13133
  26. Man SM, 2017, IMMUNOL REV, V277, P61, DOI 10.1111/imr.12534
  27. Mattos KA, 2011, CELL MICROBIOL, V13, P259, DOI 10.1111/j.1462-5822.2010.01533.x
  28. Pontillo A, 2013, INFECT GENET EVOL, V19, P274, DOI 10.1016/j.meegid.2013.06.006
  29. Quaresma JAS, 2006, VIROLOGY, V345, P22, DOI 10.1016/j.virol.2005.09.058
  30. Quaresma JAS, 2017, MEDIAT INFLAMM, DOI 10.1155/2017/6793968
  31. Saini C, 2017, IMMUNOL LETT, V184, P61, DOI 10.1016/j.imlet.2017.02.013
  32. Sharma D, 2016, J CELL BIOL, V213, P617, DOI 10.1083/jcb.201602089
  33. Sinsimer D, 2010, INFECT IMMUN, V78, P293, DOI 10.1128/IAI.00816-09
  34. Tavares AH, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002595
  35. Tay SS, 2014, CURR DERMATOL REP, V3, P13, DOI 10.1007/s13671-013-0063-9
  36. Uchiyama R, 2015, ARCH IMMUNOL THER EX, V63, P1, DOI 10.1007/s00005-014-0301-2
  37. Vanaja SK, 2015, TRENDS CELL BIOL, V25, P308, DOI 10.1016/j.tcb.2014.12.009
  38. Zamboni DS, 2015, IMMUNOL REV, V265, P156, DOI 10.1111/imr.12291

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - IMT
Artigos e Materiais de Revistas Científicas - LIM/53
Artigos e Materiais de Revistas Científicas - ODS/03